Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Escalating Doses of Inotuzumab Ozogamicin (DA-EPOCH-InO) in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

NCT03991884 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT03991884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03991884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Escalating Doses of Inotuzumab Ozogamicin (DA-EPOCH-InO) in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Lead sponsor
University of Washington
Phase
Phase 1
Overall status
Completed
Start date
September 24, 2019
Completion date
June 28, 2023
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent b acute lymphoblastic leukemia, recurrent b lymphoblastic lymphoma, refractory b acute lymphoblastic leukemia, refractory b lymphoblastic lymphoma